Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 3/20 | 0.38 |
| ▸ | ADH1A | P07327 | 3/20 | 0.38 |
| ▸ | ADH7 | P40394 | 3/20 | 0.38 |
| ▸ | ADH1C | P00326 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995359 | 0.89 | GNAI3 (0.39) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL20407305 | 0.84 | — | — | |
| SCHEMBL16207271 | 0.84 | ADH1B (0.46) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL2183070 | 0.81 | ADH1B (0.45) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL1306927 | 0.80 | HRH3 (0.46) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3321937 | 0.80 | ADH1B (0.43) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3950791 | 0.79 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL1307277 | 0.79 | HRH3 (0.50) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL22294037 | 0.78 | CYP2C19 (0.38) | HPGDPAOXMEN1KMT2AACE2 | |
| SCHEMBL17207595 | 0.77 | CARM1 (0.43) | HPGDPAOXMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | claimed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | claimed |
| EP-2576586-B1 | C-28 AMIDES OF MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | ADH1B 2172/4885ADH1A 2338/4885ADH7 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.